866 related articles for article (PubMed ID: 15150106)
21. Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance.
Ng CP; Zisman A; Bonavida B
Prostate; 2002 Dec; 53(4):286-99. PubMed ID: 12430140
[TBL] [Abstract][Full Text] [Related]
22. The proteasome inhibitor MG132 potentiates TRAIL receptor agonist-induced apoptosis by stabilizing tBid and Bik in human head and neck squamous cell carcinoma cells.
Sung ES; Park KJ; Choi HJ; Kim CH; Kim YS
Exp Cell Res; 2012 Aug; 318(13):1564-76. PubMed ID: 22513214
[TBL] [Abstract][Full Text] [Related]
23. Roscovitine sensitizes breast cancer cells to TRAIL-induced apoptosis through a pleiotropic mechanism.
Ortiz-Ferrón G; Yerbes R; Eramo A; López-Pérez AI; De Maria R; López-Rivas A
Cell Res; 2008 Jun; 18(6):664-76. PubMed ID: 18458681
[TBL] [Abstract][Full Text] [Related]
24. Down-regulation of intracellular anti-apoptotic proteins, particularly c-FLIP by therapeutic agents; the novel view to overcome resistance to TRAIL.
Hassanzadeh A; Farshdousti Hagh M; Alivand MR; Akbari AAM; Shams Asenjan K; Saraei R; Solali S
J Cell Physiol; 2018 Oct; 233(10):6470-6485. PubMed ID: 29741767
[TBL] [Abstract][Full Text] [Related]
25. Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes.
Leverkus M; Neumann M; Mengling T; Rauch CT; Bröcker EB; Krammer PH; Walczak H
Cancer Res; 2000 Feb; 60(3):553-9. PubMed ID: 10676636
[TBL] [Abstract][Full Text] [Related]
26. Specific cleavage of Mcl-1 by caspase-3 in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in Jurkat leukemia T cells.
Weng C; Li Y; Xu D; Shi Y; Tang H
J Biol Chem; 2005 Mar; 280(11):10491-500. PubMed ID: 15637055
[TBL] [Abstract][Full Text] [Related]
27. Persistent c-FLIP(L) expression is necessary and sufficient to maintain resistance to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in prostate cancer.
Zhang X; Jin TG; Yang H; DeWolf WC; Khosravi-Far R; Olumi AF
Cancer Res; 2004 Oct; 64(19):7086-91. PubMed ID: 15466204
[TBL] [Abstract][Full Text] [Related]
28. Reactive oxygen species regulate caspase activation in tumor necrosis factor-related apoptosis-inducing ligand-resistant human colon carcinoma cell lines.
Izeradjene K; Douglas L; Tillman DM; Delaney AB; Houghton JA
Cancer Res; 2005 Aug; 65(16):7436-45. PubMed ID: 16103097
[TBL] [Abstract][Full Text] [Related]
29. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players.
Hesry V; Piquet-Pellorce C; Travert M; Donaghy L; Jégou B; Patard JJ; Guillaudeux T
Prostate; 2006 Jun; 66(9):987-95. PubMed ID: 16541419
[TBL] [Abstract][Full Text] [Related]
30. Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs.
Tomek S; Horak P; Pribill I; Haller G; Rössler M; Zielinski CC; Pils D; Krainer M
Gynecol Oncol; 2004 Jul; 94(1):107-14. PubMed ID: 15262127
[TBL] [Abstract][Full Text] [Related]
31. Membrane expression of DR4, DR5 and caspase-8 levels, but not Mcl-1, determine sensitivity of human myeloma cells to Apo2L/TRAIL.
Gómez-Benito M; Martinez-Lorenzo MJ; Anel A; Marzo I; Naval J
Exp Cell Res; 2007 Jul; 313(11):2378-88. PubMed ID: 17462628
[TBL] [Abstract][Full Text] [Related]
32. Sulindac sulfide-induced apoptosis is enhanced by a small-molecule Bcl-2 inhibitor and by TRAIL in human colon cancer cells overexpressing Bcl-2.
Sinicrope FA; Penington RC
Mol Cancer Ther; 2005 Oct; 4(10):1475-83. PubMed ID: 16227396
[TBL] [Abstract][Full Text] [Related]
33. TRAIL (APO-2L) induces apoptosis in human prostate cancer cells that is inhibitable by Bcl-2.
Munshi A; Pappas G; Honda T; McDonnell TJ; Younes A; Li Y; Meyn RE
Oncogene; 2001 Jun; 20(29):3757-65. PubMed ID: 11439339
[TBL] [Abstract][Full Text] [Related]
34. Glucocorticoid cotreatment induces apoptosis resistance toward cancer therapy in carcinomas.
Herr I; Ucur E; Herzer K; Okouoyo S; Ridder R; Krammer PH; von Knebel Doeberitz M; Debatin KM
Cancer Res; 2003 Jun; 63(12):3112-20. PubMed ID: 12810637
[TBL] [Abstract][Full Text] [Related]
35. eNOS protects prostate cancer cells from TRAIL-induced apoptosis.
Tong X; Li H
Cancer Lett; 2004 Jul; 210(1):63-71. PubMed ID: 15172122
[TBL] [Abstract][Full Text] [Related]
36. Interrelated roles for Mcl-1 and BIM in regulation of TRAIL-mediated mitochondrial apoptosis.
Han J; Goldstein LA; Gastman BR; Rabinowich H
J Biol Chem; 2006 Apr; 281(15):10153-63. PubMed ID: 16478725
[TBL] [Abstract][Full Text] [Related]
37. Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11.
Ray S; Almasan A
Cancer Res; 2003 Aug; 63(15):4713-23. PubMed ID: 12907654
[TBL] [Abstract][Full Text] [Related]
38. Ectopic expression of Bcl-2 and Bcl-xL inhibits apoptosis induced by TNF-related apoptosis-inducing ligand (TRAIL) through suppression of caspases-8, 7, and 3 and BID cleavage in human acute myelogenous leukemia cell line HL-60.
Lamothe B; Aggarwal BB
J Interferon Cytokine Res; 2002 Feb; 22(2):269-79. PubMed ID: 11911810
[TBL] [Abstract][Full Text] [Related]
39. Drug-mediated sensitization to TRAIL-induced apoptosis in caspase-8-complemented neuroblastoma cells proceeds via activation of intrinsic and extrinsic pathways and caspase-dependent cleavage of XIAP, Bcl-xL and RIP.
Mühlethaler-Mottet A; Bourloud KB; Auderset K; Joseph JM; Gross N
Oncogene; 2004 Jul; 23(32):5415-25. PubMed ID: 15094781
[TBL] [Abstract][Full Text] [Related]
40. TNF-related apoptosis-inducing ligand (TRAIL) frequently induces apoptosis in Philadelphia chromosome-positive leukemia cells.
Uno K; Inukai T; Kayagaki N; Goi K; Sato H; Nemoto A; Takahashi K; Kagami K; Yamaguchi N; Yagita H; Okumura K; Koyama-Okazaki T; Suzuki T; Sugita K; Nakazawa S
Blood; 2003 May; 101(9):3658-67. PubMed ID: 12506034
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
